Immunotherapy is an important treatment approach for advanced melanoma, a type of skin cancer that can spread to other parts of the body. These treatments help the immune system recognize and attack cancer cells. Different immunotherapy medicines work through specific immune pathways, and treatment selection depends on disease characteristics, previous therapies, and overall health.
Advanced melanoma occurs when melanoma spreads beyond its original location to nearby lymph nodes or distant organs. Treatment decisions depend on the stage of the disease, the location of tumors, previous treatments, and the patient's overall health. Immunotherapy has become an important option because it can strengthen the body's immune response against cancer cells.
Immunotherapy uses medicines that help the immune system recognize and attack cancer cells. Some melanoma cells avoid immune detection by interfering with natural immune responses. Certain immunotherapy medicines block these mechanisms, allowing immune cells to respond more effectively.
Immune checkpoint inhibitors are widely used for advanced melanoma. These treatments target proteins that regulate immune activity and can help restore the immune system's ability to attack cancer cells.
Common immunotherapy options include:
Pembrolizumab: This medicine blocks the PD-1 immune checkpoint protein, helping immune cells recognize and attack cancer cells.
Nivolumab: Another PD-1 inhibitor, nivolumab can be used alone or in combination with other immunotherapy medicines, depending on the treatment setting.
Ipilimumab: This medicine blocks CTLA-4, a protein that limits immune cell activation. It may be combined with nivolumab for selected patients.
Nivolumab and relatlimab: This combination targets PD-1 and LAG-3, two immune checkpoint proteins. It can help improve immune activity against advanced melanoma.
Treatment schedules and eligibility vary according to the medicine, disease characteristics, and applicable clinical guidelines. An oncologist evaluates the potential benefits and risks before recommending a particular regimen.
Immunotherapy can produce durable responses in some people with advanced melanoma. Unlike treatments that directly target cancer cells, checkpoint inhibitors help the immune system recognize and respond to cancer. However, not every patient responds, and treatment outcomes differ between individuals.
Immune activation can also affect healthy tissues, producing side effects that range from mild to severe. Medical monitoring is essential during treatment and after certain therapies have ended.
Important considerations include:
Potential benefits: Some patients experience substantial tumor shrinkage or prolonged disease control. Responses can sometimes continue after treatment ends, although this is not guaranteed.
Common side effects: Fatigue, skin rash, itching, diarrhea, and joint discomfort may occur during immunotherapy.
Immune related complications: Inflammation can affect organs such as the lungs, liver, intestines, thyroid, and other endocrine glands. Severe complications may require urgent medical treatment.
Combination treatment risks: Using two immunotherapy medicines together may increase the likelihood of significant side effects compared with some single-drug regimens.
Ongoing assessment: Doctors may use imaging tests, physical examinations, laboratory tests, and symptom reviews to evaluate treatment response and identify complications.
Patients should report new or worsening symptoms promptly, particularly breathing difficulties, persistent diarrhea, severe abdominal pain, jaundice, or unusual weakness. Some immune-related side effects require immediate medical attention.
The choice of immunotherapy depends on individual medical circumstances, including previous treatment, tumor characteristics, coexisting conditions, and personal preferences. Clinical trials may also provide access to investigational approaches for eligible patients. Discussions with an oncology team can help clarify treatment goals, expected monitoring, potential side effects, and alternative options for managing advanced melanoma.